India, Oct. 21 -- Kyverna Therapeutics (KYTX) reported one-year data from its Phase 2 KYSA-8 trial showing sustained benefits of miv-cel in stiff person syndrome.
Among 26 patients, walking performance improved by a median 49%, while 92% remained free of chronic immunotherapies for the disease. No high-grade CRS or ICANS cases were reported.
Currrently, KYTX is trading at $5.97, down 1.16%.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....